Systemic therapy

Phase 2Small molecule

Bristol-Myers Squibb

Systemic therapy is one of 265 small molecule programs targeting Bone Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

264

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

LymphomaActive, not recruiting

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Prostate CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Bladder CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Bone MetastasisPreclinical

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

Liver CancerPreclinical

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Colorectal CancerPreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Bladder CancerPhase 2/Phase 3

Active, not recruiting

Multiple MyelomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Tykerb

GSK

Preclinical

80 3

Systemic therapy

Bristol-Myers Squibb

Phase 2

1 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Prolia

Amgen

Preclinical

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

MS Contin

Merck & Co.

Preclinical

2 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Efficacy and Safety

NCT06427252

Q3 2027

Phase 2Recruiting

Prostate Cancer

NCT05223803

Phase 3Recruiting

Oligometastatic

NCT06190782

Q3 2028

N/ARecruiting

Colorectal Cancer

NCT06449937

Phase 3Recruiting

Second-Line Therapy

NCT06841172

Phase 2Recruiting

Radiation Therapy

NCT06613269

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07274774·184 enrolled

Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06254248·50 enrolled

Radiation Therapy2 trials

68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06613269·40 enrolled

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03523351·78 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

Completed·FFudan University·Phase 2·NCT03904927·104 enrolled

Colorectal Cancer1 trial

Local Liver Treatment for Multi-organ Colorectal Cancer Metastases

Recruiting·—·N/A·NCT06449937·130 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM

Active, not recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06427252·50 enrolled

10 more indications

Liver Cancer1 trial

A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data

Not yet recruiting·XXuhua Duan··NCT07156617·2,000 enrolled

Prostate Cancer1 trial

TERPS Trial for de Novo Oligometastic Prostate Cancer

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT05223803·122 enrolled

Multiple Myeloma1 trial

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06160167·4,204 enrolled

Breast Cancer1 trial

Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy

Not yet recruiting·—·N/A·NCT05285332·362 enrolled

Bladder Cancer1 trial

Radiation Therapy in Unresectable Gall Bladder Cancer

Recruiting·TTata Memorial Centre·Phase 2/3·NCT06214572·249 enrolled

Second-line Therapy1 trial

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

Recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT06841172·132 enrolled

Recurrent Tumor1 trial

SBRT for Extra-cranial Oligorecurrent Tumor

Unknown status·KKorea Cancer Center Hospital·Phase 2·NCT02410187·1 enrolled

Oligometastatic1 trial

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Recruiting·FFudan University·Phase 3·NCT06190782·354 enrolled

Lymphoma1 trial

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06422247·307 enrolled

Bone Metastasis1 trial

Bone Metastasis and Surgery in Breast Cancer

Completed·FFederation of Breast Diseases Societies··NCT02125630·460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Systemic therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Systemic therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Systemic therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

Systemic therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q3 2028

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Radiation Therapy2 trials

Esophageal Squamous Cell Carcinoma1 trial

Colorectal Cancer1 trial

Efficacy and Safety1 trial

Liver Cancer1 trial

Prostate Cancer1 trial

Multiple Myeloma1 trial

Breast Cancer1 trial

Bladder Cancer1 trial

Second-line Therapy1 trial

Recurrent Tumor1 trial

Oligometastatic1 trial

Lymphoma1 trial

Bone Metastasis1 trial

References

Drug Info

Quick Facts

Related News